---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-254560"
form_type: "8-K"
ticker: "VRDN"
cik: "0001590750"
company_name: "Viridian Therapeutics, Inc.\\DE"
filed_at: "2026-06-03T11:00:22+00:00"
generated_at: "2026-06-03T11:05:43.414962+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.15
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Viridian Therapeutics Annual Meeting approves director elections, KPMG ratification, say-on-pay

## Summary
- Tomas Kiselak and Jennifer K. Moses elected as Class II directors until 2029.
- KPMG LLP ratified as independent auditor for FY2026; 92.9M for, 0.5M against.
- Advisory say-on-pay approved with 83.5M for, 3.1M against.
- Board sets future say-on-pay votes every year based on advisory vote results.

## SEC filing metadata
- accession: 0001193125-26-254560
- form_type: 8-K
- ticker: VRDN
- cik: 0001590750
- company_name: Viridian Therapeutics, Inc.\DE
- filed_at: 2026-06-03T11:00:22+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.15
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1590750/000119312526254560/0001193125-26-254560-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1590750/000119312526254560/d117727d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-254560
- JSON: https://secwatch.observer/filing/0001193125-26-254560.json
- Plain text: https://secwatch.observer/filing/0001193125-26-254560.txt

## Key facts
- Shareholder Votes
  Viridian Therapeutics, Inc.\DE shareholders approved Ratification of the selection of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-06-02 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2026-06-02
  source text: 2. Ratification of the selection of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026: For Against Abstentions Broker Non-Votes 92,866,008 512,582 193,660 —
  evidence_url: https://www.sec.gov/Archives/edgar/data/1590750/000119312526254560/0001193125-26-254560-index.htm
- Shareholder Votes
  Viridian Therapeutics, Inc.\DE shareholders approved Election of two Class II director nominees to serve until the 2029 Annual Meeting of Stockholders at the 2026-06-02 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2026-06-02
  source text: 1. Election of the two Class II director nominees to serve until the 2029 Annual Meeting of Stockholders: For Withheld Broker Non-Votes Tomas Kiselak 72,363,500 14,475,646 6,733,104 Jennifer K. Moses 86,378,842 460,304 6,733,104
  evidence_url: https://www.sec.gov/Archives/edgar/data/1590750/000119312526254560/0001193125-26-254560-index.htm
- Shareholder Votes
  Viridian Therapeutics, Inc.\DE shareholders approved Approval, on an advisory basis, of the frequency of holding an advisory vote on the compensation of the Company’s named executive officers at the 2026-06-02 meeting.
  - Proposal: say on pay frequency
  - Outcome: passed
  - Meeting: 2026-06-02
  source text: 4. Approval, on an advisory basis, of the frequency of holding an advisory vote on the compensation of the Company’s named executive officers: 1 Year 2 Years 3 Years Abstain 86,084,347 29,762 517,682 207,355
  evidence_url: https://www.sec.gov/Archives/edgar/data/1590750/000119312526254560/0001193125-26-254560-index.htm
- Shareholder Votes
  Viridian Therapeutics, Inc.\DE shareholders approved Approval, on an advisory basis, of the compensation of the Company’s named executive officers at the 2026-06-02 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2026-06-02
  source text: 3. Approval, on an advisory basis, of the compensation of the Company’s named executive officers: For Against Abstentions Broker Non-Votes 83,512,086 3,113,724 213,336 6,733,104
  evidence_url: https://www.sec.gov/Archives/edgar/data/1590750/000119312526254560/0001193125-26-254560-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.